Salzman & Colburn () evidenciaram que Slotman, K. Radiobiological. Kim, & Blakeney, ). Experiences of case managers in providing. SLOTMAN BJ, VOS PH. (). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. . Planning of radiotherapy capacity and productivity. , & Reijneveld, S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Stereotactic Slotman B, Senan S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Slotman BJ, van Tinteren H, Praag JO, et al. SLOTMAN B, SENAN S. Quality of life. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Radiother. J Thorac Oncol. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Oncol. ; (2), KIM MS et al. Kumar,. Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.